Feb 1, 2026
How do MONALEESA trial overall survival results for ribociclib compare with other CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer?
, as tested in the program, is the only CDK4/6 inhibitor with consistent, statistically significant overall survival (OS) advantages reported across multiple phase III trials (MONALEESA‑2, ‑3, and ‑7)...